MediciNova moves closer to Avigen acquisition
This article was originally published in Scrip
MediciNova has reached an "understanding of certain key terms" for its proposed acquisition of fellow California-based company Avigen. The two firms will continue non-binding discussions on a possible deal, which Avigen said could be presented to shareholders in the third quarter.
You may also be interested in...
Novel antibody-drug conjugate receives approval in Japan for second-line breast cancer, providing another push to Japanese firm’s strategic plan to build up its oncology operations.
Collaboration with fundraising Tokyo-based venture builds mid-sized firm's interest in cell-based therapies in a highly supportive regulatory environment.
New long-term clinical data with Takeda’s dengue vaccine contender show a durable response against all four serotypes and support the dosing regimen in an ongoing pivotal study.